As the safety of folinic acid administration and its efficacy for reducing the toxicity of MTX remain controversial, we assessed the effect of folinic acid administration after MTX treatment for GVHD prophylaxis on the incidence of oral mucositis and acute GVHD. We retrospectively analyzed data for 118 patients who had undergone allogeneic hematopoietic SCT and had received MTX for GVHD prophylaxis. Multivariate analysis showed that systemic folinic acid administration significantly reduced the incidence of severe oral mucositis (odds ratio (OR) ¼ 0.13, 95% confidence interval (CI) 0.04-0.73, P ¼ 0.014). There was also a tendency for a lower incidence of severe oral mucositis in patients who received folinic acid mouthwash (OR ¼ 0.39, 95%CI 0.15-1.00, P ¼ 0.051). No significant difference was observed in the incidence of acute GVHD between patients who received systemic folinic acid administration and those who did not (P ¼ 0.88). Systemic folinic acid administration and mouthwash appear to be useful for reducing the incidence of severe oral mucositis in patients who have received allogeneic hematopoietic SCT using MTX as GVHD prophylaxis.
Introduction
Oral mucositis is one of the most common complications associated with allogeneic hematopoietic SCT, occuring in 60-90% of patients who have received SCT. [1] [2] [3] Oral mucositis is associated with severe pain, which can lead to anorexia and dehydration. A large population of patients with severe oral mucositis require total parenteral nutrition and opioid analgesics. 4 Severe oral mucositis is associated with not only severe pain but also poor clinical and economic outcomes. 5 Oral mucositis is caused mainly by the toxicity associated with chemotherapy and TBI as a conditioning regimen; however, it is also associated with the use of MTX for GVHD prophylaxis. 6, 7 Although several studies have shown that folinic acid administration reduced the toxicity of MTX, [8] [9] [10] the efficacy and safety of folinic acid administration remain controversial. Ruutu et al. 11 reported that folinic acid was administered after MTX in 37 (45.7%) of 81 European Group for Blood and Marrow Transplantation (EBMT) centers, and Bhurani et al. 12 reported that folinic acid was administered after MTX in 8 (44.4%) of 8 centers in Australia and New Zealand. More than half of the centers surveyed in those studies did not use systemic folinic acid administration because of the lack of support for its efficacy or because of the risk of acute GVHD being induced by folinic acid.
Therefore, this study was performed to assess the effects of systemic folinic acid administration after MTX for GVHD prophylaxis on the incidence of oral mucositis and acute GVHD.
Patients and methods
We retrospectively analyzed data for 141 consecutive patients who had undergone allogeneic hematopoietic SCT and had received MTX for GVHD prophylaxis between March 2006 and December 2009 in Stem Cell Transplantation Center of Hokkaido University Hospital. We excluded seven patients whose data were insufficient. Furthermore, we excluded 16 patients who failed to achieve engraftment because we hypothesized that duration of neutropenia was a risk factor for the development of mucositis, and that engraftment failure might be an extremely strong risk factor for the development of mucositis. Therefore, data for 118 patients were analyzed in this study. The study protocol was approved by the review board of Hokkaido University Graduate School of Medicine.
Conditioning regimens and transplantation procedures
Most of the conventional conditioning regimens consisted of TBI (12 Gy in six fractions) plus CY (60 mg/kg once daily i.v. for 2 days, total dose of 120 mg/kg)±VP-16 (etoposide) (15 mg/kg once daily i.v. for 2 days, total dose of 30 mg/kg), 13 and most of the reduced-intensity conditioning regimens consisted of fludarabine (30 mg/m 2 once daily i.v. for 6 days, total dose of 180 mg/m 2 ) plus oral BU (4 mg/kg p.o. in divided doses daily for 2 days, total dose of 8 mg/kg) or i.v. BU (3.2 mg/kg i.v. in divided doses daily for 2 days, total dose of 6.4 mg/kg) plus low-dose TBI (4 Gy in two fractions).
14 CsA (3 mg/kg) or tacrolimus (FK, 0.03 mg/kg) and short-course MTX were used for GVHD prophylaxis. MTX was given at a dose of 15 or 10 mg/m 2 on day 1 and at a dose of 10 or 7 mg/m 2 on day 3 and day 6.
Supportive care and infection prophylaxis Granulocyte CSF was administered from day 5 until engraftment. Levofloxacin was administered for prevention of bacterial infections until engraftment, and an antifungal (fluconazole, itraconazole or micafungin) was administered for prevention of fungal infections. Oral acyclovir was given from day À7 to day 35 for prevention of HSV infection.
Systemic folinic acid administration and mouthwash Folinic acid was given i.v. at the same dose as that used for each administration of MTX at 12, 18 and 24 h after administration of MTX on days 1 and 3, and at 24, 30 and 36 h after administration of MTX on day 6. Folinic acid mouthwash (13.0% folinic acid) was given four times a day from day 1 to day 7. Systemic folinic acid administration and folinic acid mouthwash were given according to physicians' discretion. They were given to the patients who were considered by physicians to be at high risk for severe oral mucositis. For example, conventional conditioning regimens, female gender and higher doses of MTX were considered as high risk for severe oral mucositis.
Grading of oral mucositis
Oral mucositis was graded by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 3.0. The criteria for oral mucositis were as follows: Grade 0, none; Grade 1, erythema of the mucosa; Grade 2, patchy ulcerations of pseudomembranes; Grade 3, confluent ulcerations or pseudomembranes, bleeding with minor trauma; Grade 4, tissue necrosis, significant spontaneous bleeding, life-threatening consequences. Severe oral mucositis was defined as grade 3 or 4 oral mucositis. The incidence and severity of oral mucositis were evaluated daily by physicians and nurses. Dentists and dental hygienists evaluated oral mucositis at least once per week. The grading of oral mucositis was assigned at the time of evaluation.
Evaluation of GVHD Acute GVHD was graded according to the consensus criteria. 15 
Statistical analysis
Univariate analyses were performed using the w 2 -test and Fisher's exact test, as appropriate. Factors with a P-value of 0.2 or less in the univariate analyses were included in the multivariate analysis. Stepwise multivariate logistic regression models were used to analyze the influence of selected variables on the risk of severe oral mucositis. Cumulative incidence of acute GVHD was calculated using the Gray method, 16 considering death without acute GVHD or relapse as competing events. Similarly, in the analysis of relapse incidence, death resulting from other causes was considered as a competing risk. In the analysis of nonrelapse mortality, relapse was considered as a competing risk. JMP software version 8.0.2 (SAS Institute, Cary, NC, USA) was used for most of the statistical analyses. Analysis of cumulative incidences was carried out with the package 'comprsk' of the R statistical software 2.10.1 (R Foundation for Statistical Computing, Vienna, Austria; available at http://www.r-project.org/). All P-values were two sided, and differences were considered to be statistically significant when Po0.05.
Results
The patient characteristics are shown in Table 1 . Systemic folinic acid administration was given to 29 patients. The systemic folinic acid administration group had significantly higher proportions of female patients (P ¼ 0.03), patients who received higher doses of MTX (P ¼ 0.0002) and patients who received folinic acid mouthwash (Po0.0001). The mean duration of neutropenia in all patients was 18.3 days. No significant difference was observed in the duration of neutropenia between patients who received systemic folinic acid administration and those who did not (17.3 days vs 18.6 days, P ¼ 0.53). There was a difference over time. Oral mucositis was observed in 91 (77.1%) of the patients (Table 2) , and severe oral mucositis (NCI-CTCAE Grade 3 or Grade 4) was observed in 37 (31.4%) of the patients. The incidence of oral mucositis was significantly lower in patients who received systemic folinic acid administration than in patients who did not receive systemic folinic acid administration (58.6 vs 83.2%, P ¼ 0.0063), and the incidence of severe oral mucositis was also significantly lower in patients who received systemic folinic acid administration than in patients who did not receive systemic folinic acid administration (10.3 vs 38.2%, P ¼ 0.005). Table 3 shows clinical factors and results of univariate analysis of clinical factors associated with the incidence of severe oral mucositis. Severe oral mucositis was significantly associated with VP/CY/TBI (P ¼ 0.048) and duration of neutropenia (o500/mL) (P ¼ 0.0047). Systemic folinic acid administration and folinic acid mouthwash reduced the incidence of severe oral mucositis (P ¼ 0.0038 and P ¼ 0.0017, respectively). Age, gender, disease status at transplantation, GVHD prophylaxis, stem cell source and dose of MTX did not correlate with severe oral mucositis. In multivariate analysis, duration of neutropenia was significantly associated with severe oral mucositis (odds ratio (OR) ¼ 4.78, 95% confidence interval (CI) 1.77-13.9, P ¼ 0.0019), and systemic folinic acid administration significantly reduced the incidence of severe oral mucositis (OR ¼ 0.13, 95%CI 0.04-0.73, P ¼ 0.014) ( Table 4 ). There was a tendency for a higher incidence of severe oral mucositis in patients who received VP/CY/TBI (OR ¼ 2.42, 95%CI 0.86-6.99, P ¼ 0.095), and there was a tendency for a lower incidence of severe oral mucositis in patients who received folinic acid mouthwash (OR ¼ 0.39, 95%CI 0.15-1.00, P ¼ 0.051).
No significant difference was observed in the incidence of acute GVHD on day 100 after transplantation between patients who received systemic folinic acid administration and those who did not (acute GVHD grade 1-4, 71.3 vs 68.5%, P ¼ 0.88; acute GVHD grade 2-4, 49.9 vs 40.4%, P ¼ 0.36; acute GVHD grade 3-4, 6.0 vs 11.2%, P ¼ 0.51) (Figure 1 ). There was no difference in the incidence of severe oral mucositis between patients who developed acute GVHD and those who did not (GVHD grade 1-4; 29.6%, grade 0; 31.25%, P ¼ 0.87). There was no difference in the incidence of severe oral mucositis between patients who had severe acute GVHD (grade 3-4) and those who did not (GVHD grade 3-4; 16.7%, grade 1-2; 31.9%, P ¼ 0.47).
No significant difference was observed in the incidences of relapse and non-relapse mortality after transplantation between patients who received systemic folinic acid administration and those who did not (relapse, 7.4 vs 22.8%, P ¼ 0.19; non-relapse mortality, 7.8 vs 12.1%, P ¼ 0.71) (Figure 2) . Table 5 shows the effects of systemic folinic acid administration and/or mouthwash. Use of i.v. opioid analgesics and duration of inability to eat were significantly reduced in patients who received systemic folinic acid administration and/or mouthwash compared with those in patients who received neither systemic folinic acid administration nor folinic acid mouthwash. There was no difference in the duration of total parenteral nutrition between patients who received systemic folinic acid administration and/or mouthwash and patients who received neither systemic folinic acid administration nor folinic acid mouthwash.
Discussion
The efficacy and safety of folinic acid administration have been controversial so far. Less than half of the centers surveyed have used folinic acid administration. 11, 12 Therefore, we retrospectively analyzed data for 118 patients who had undergone allogeneic hematopoietic SCT and had received MTX for GVHD prophylaxis. Multivariate analysis showed that systemic folinic acid administration significantly reduced the incidence of severe oral mucositis (OR ¼ 0.13, 95%CI 0.04-0.73, P ¼ 0.014). Furthermore, use of opioid analgesics and duration of inability to eat were significantly reduced in patients who received systemic folinic acid administration.
The group of patients who received systemic folinic acid administration had significantly higher proportions of female patients (P ¼ 0.03) and patients who received higher doses of MTX (P ¼ 0.0002). Although gender did not correlate with severe oral mucositis in our study, several studies have shown that female gender is one of the risk factors for oral mucositis. 17, 18 In our retrospective study, systemic folinic acid administration was performed according to physicians'discretion. Therefore, it is likely that systemic folinic acid administration was used for patients who were considered by physicians to be at high risk for severe oral mucositis.
There are data that provide a rationale for using MTX and folinic acid in combination for GVHD prophylaxis. 19 Gratwohl et al. 20 reported that systemic folinic acid administration 6 h after each administration of MTX reduced the toxicity of MTX and maintained the effect of MTX on prevention of GVHD in dogs, and that MTX at concentrations above 10 À6 M completely abrogated thymidine uptake in lymphocytes with stimulation for 6 h in vitro. However, there are no recommendations or guidelines in adult transplant groups for the use of folinic acid following MTX. Therefore, systemic folinic acid administration was given at various doses and schedules, starting 6-24 h after MTX administration. 11, 23 We used folinic acid i.v. at the same dose as that used for each administration of MTX at 12, 18 and 24 h after administration of MTX on days 1 and 3, and at 24, 30 and 36 h after administration of MTX on day 6. We decided the dose and timing of systemic folinic acid administration according to the dose and timing of systemic folinic acid administration after high-dose MTX.
Although there was no significant difference in the incidence and severity of acute GVHD in our study, our dose of folinic acid, which is about three times higher than that of the pediatric recommendation, might be in excess of those required. Further studies are needed to establish the optimal dose and timing of systemic folinic acid administration.
Although there is no evidence to support the use of folinic acid mouthwash for prevention of mucositis, folinic acid mouthwashes have been given to patients who received MTX administration in some centers. [24] [25] [26] In our study, multivariate analysis showed that there was a tendency for a lower incidence of severe oral mucositis in patients who received folinic acid mouthwash (OR ¼ 0.39, 95%CI 0.15-1.00, P ¼ 0.051). Not only systemic folinic acid administration but also folinic acid mouthwash significantly reduced the use of opioid analgesics and the duration of inability to eat. Therefore, it is likely that folinic acid mouthwash had a positive effect on the prevention of severe oral mucositis. In multivariate analysis, duration of neutropenia (more than 21 days) was significantly associated with severe oral mucositis (OR ¼ 4.78, 95%CI 1.77-13.9, P ¼ 0.0019). The mean duration of neutropenia was 18.3 days in our study. Therefore, the cutoff point of duration of neutropenia appeared to be 3 weeks (21 days). The use of folinic acid did not reduce the duration of neutropenia in our study (17.3 days vs 18.6 days, P ¼ 0.53). It is important to reduce the duration of neutropenia to prevent severe oral mucositis.
Hoyt et al. 27 reported that etoposide induces more severe mucositis than dose CY when added to TBI. In our study, there was a tendency for a higher incidence of severe oral mucositis in patients who received VP/CY/TBI (OR ¼ 2.42, 95%CI 0.86-6.99, P ¼ 0.095). A VP/CY/TBI regimen may increase the incidence of severe oral mucositis compared with the effects of other conditioning regimens. In patients with a high risk of severe oral mucositis, use of MTX for GVHD prophylaxis may cause more severe oral mucositis. Therefore, systemic folinic acid administration may be useful to reduce the incidence of severe oral mucositis in patients who have received a VP/CY/TBI regimen.
Although Takahashi et al. 1 reported that the severity of oral mucositis was reduced in reduced intensity stem cell transplantation (RIST) patients compared with that in conventional stem cell transplantation (CST) patients, no significant difference was observed in the incidence of severe oral mucositis between patients who received CST and those who received RIST in our study. Several studies have shown that severe oral mucositis was correlated with TBI. 28 One reason for no significant difference being found in our study might be the use of TBI in most RIST patients.
Although Sonis et al. 5 reported that oral mucositis is associated with significantly worse economic outcomes, there was no difference in the duration of total parenteral nutrition in our study. We were not able to show the cost effectiveness of the use of folinic acid. Further studies are needed to clarify the cost effectiveness.
In this retrospective study, systemic folinic acid administration and mouthwash appear to be useful for reducing the incidence of severe oral mucositis in those patients who were considered by physicians to be at high risk for severe oral mucositis. Further prospective controlled studies are needed to assess the efficacy of systemic folinic acid administration and mouthwash.
